Psilocybin for Treatment‑Resistant Depression in Veterans: The PIVOT Study

Principal Investigator: Lori Davis

Many U.S. military Veterans live with depression that does not improve despite multiple standard treatments. For those with treatment‑resistant depression (TRD)—often compounded by post‑traumatic stress disorder (PTSD)—the need for new, effective therapies is urgent. Early research in civilian populations suggests that psilocybin, given under structured therapeutic support, may produce rapid and meaningful improvements in depressive symptoms. However, its effects have never been rigorously tested in Veterans, who often have unique clinical histories and comorbidities. The PIVOT study is the first large‑scale, federally sponsored clinical trial to evaluate psilocybin’s safety and efficacy specifically in Veterans with TRD, including those with and without PTSD. The findings could influence future VA mental health treatment pathways, expand therapeutic options, and potentially offer relief to individuals who have not benefited from traditional antidepressant medications.

The PIVOT study (NCT07226232), sponsored by the VA Office of Research and Development, is a multi‑site Phase 3 randomized controlled trial designed to evaluate psilocybin-assisted therapy for U.S. military Veterans living with treatment‑resistant depression (TRD), with or without co‑occurring PTSD. TRD is a severe, persistent condition in which Veterans have not responded adequately to multiple prior antidepressants, contributing to significant suffering and functional impairment. Although psilocybin has shown promise in civilian studies, little is known about its effectiveness or safety in Veteran populations.

The study will enroll approximately 240 Veterans, aged 18 to 75, across several VA medical centers nationwide. After screening and completing preparatory visits, participants are randomly assigned, under blinded conditions, to receive one of two psilocybin doses during their first dosing session. One month later, all participants return for a second dosing session in which they receive the same dose they were assigned initially.

Each dosing visit includes structured preparation, administration, and integration support provided by trained facilitators. Participants are closely monitored throughout the sessions, and outcomes are assessed by independent evaluators who remain masked to treatment assignment.

The primary measure of effectiveness is improvement in depression severity using the Montgomery–Åsberg Depression Rating Scale (MADRS) at two weeks after dosing. Secondary and exploratory outcomes evaluate side‑effect burden, PTSD symptom changes (for those with PTSD at baseline), additional depression rating scales, and participant‑reported outcomes.

Safety monitoring is extensive: the study tracks all expected and unexpected side effects, cardiovascular and medical risk factors, concurrent medications, and any psychiatric changes. Long‑term follow‑up extends through six months to understand durability and safety over time.

Because psilocybin is a controlled substance and remains investigational, PIVOT provides a critical scientific foundation for understanding whether this therapy is safe, effective, and appropriate for use within the VA health system. If beneficial, psilocybin‑assisted therapy could represent a significant advancement for Veterans living with severe, hard‑to‑treat depression.